Record Revenue and Continued Growth Streak
Net revenue of $18.9M in Q2 FY2026, a 16.3% year-over-year increase; marks the thirteenth consecutive quarter of year-over-year revenue and profit growth.
Strong Home Care Performance
Direct Home Care revenue grew 18.4% YoY to $17.3M; annualized home care revenue per weighted-average direct sales representative reached $1.2M (above target range of $1.0M–$1.1M); averaged 58 direct reps in Q2 with planned expansion to 61.
Improved Profitability and Margins
Gross profit increased to $14.8M (78.4% of net revenues) from $12.6M (77.7% prior year). Operating income rose ~42.4% YoY (CFO reported operating income of $3.6M or 19.2% of sales vs $2.5M prior year). Net income grew 40.3% YoY to $2.8M; diluted EPS $0.32 vs $0.22 prior year.
Balance Sheet Strength
Cash on hand of $13.8M, no debt, working capital of $36.2M, and total shareholders' equity of $45.4M.
Shareholder Return Initiatives
Board approved a $10M stock repurchase authorization (authorized in Q1); $3.8M of share repurchases executed in the six months ended Dec 31, 2025.
Commercial and Market Expansion Wins
Executed 25 payer contracts in H1 FY2026, adding ~2.9M covered lives to the company's >270M already under contract; home care distributor channel grew 12.1% YoY to $900K.
Operational and Go-to-Market Enhancements
Completed manufacturing optimization (US-based operations and assembly), implemented CRM and Smart Order e-prescribe (over one-third of orders on e-prescribe in Q2), and engaged in marketing/education (3 national trade shows, regional events, and 3 virtual CEUs with 655 attendees).
Large Addressable Opportunity Identified
Company highlights ~923,000 diagnosed bronchiectasis patients in the U.S. with only 16% using HFCWO therapy; estimates suggest >4M undiagnosed individuals — framing a substantial long-term market opportunity.